Skip to main content

Table 6 Summary of multivariate analysis in all patients with neoadjuvant chemotherapy showing the odds ratio (95% confidence interval) of variables significantly associated with PD-L1 scoring methods and sTIL level

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

FactorTC22C3TCIC22C3IC22C3sTIL level
Race/ethnicity
 White+Latino vs. Black0.10 (0.01, 0.76)a   
 Others vs. BlackNS   
Histologic grade
 3 vs. 1 + 2 7.27 (1.94, 27.24)b4.94 (1.31,18.73)a4.38 (1.84, 10.45)c
sTIL level
 ≥ 10% vs. < 10%6.10 (1.18, 41.16)a6.71 (2.37, 18.99)c4.39 (1.49, 12.85)b 
Receptor group
 ER/PR pos vs. TNBC0.10 (0.01, 0.63)b   
 HER2 vs. TNBCNS   
Tumor size
 > 2 to 5 cm vs. ≤2 cm   NS
 > 5 cm vs. ≤2 cm   0.26 (0.09, 0.76)a
  1. NS not significant
  2. aP value < 0.05–0.01
  3. bP value < 0.01–0.001
  4. cP value < 0.001